ATP2C2

Across TCGA pan-cancer cohorts, ATP2C2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP2C2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP2C2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2C2 expression acts as an unfavorable survival marker.

LUAD, COAD, and HNSC are the cancer types where ATP2C2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.381	0.817	<.001	38	view →
COAD	DFS	Median	III,IV	0.658	1.000	.031	6	view →
HNSC	DFS	Median	All	0.599	0.846	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP2C2–LUAD (DFS)

Open the LUAD breakdown →